Inflammatory bowel disease surgery in the biologic era.

World J Gastrointest Surg 2016 May;8(5):363-70

Linda Ferrari, Mukta K Krane, Alessandro Fichera, University of Washington Medical Center, Seattle, WA 98195-6410, United States.

Anti-tumour necrosis factor (TNF)-α therapy has revolutionized inflammatory bowel disease (IBD) treatment. Infliximab and adalimumab either as monotherapy or in combination with an immunomodulator are able to induce clinical and biological remission in patients with moderate and severe Crohn's disease (CD) and ulcerative colitis (UC). These new therapies have led to a shift in the goals of IBD management from just controlling clinical symptoms to preventing disease progression. However, despite these advances in medical therapy, surgery is still required in 30%-40% of patients with CD and 20%-30% of patients with UC at some point during their lifetime. While biologics certainly play a major role in the medical treatment of IBD, there is concern about the effects of these anti-TNF-α agents on postoperative complications and morbidity. The purpose of this article is to review the role of surgery in the treatment of IBD in the age of biologics and the impact of these medications on per-operative outcomes. In this manuscript we review the relationship between biologic agents and surgery in the treatment of IBD. We also discuss in detail the periopetative risks and complications.

Download full-text PDF

Source
http://dx.doi.org/10.4240/wjgs.v8.i5.363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872064PMC
May 2016
2 Reads

Publication Analysis

Top Keywords

treatment ibd
12
surgery treatment
8
bowel disease
8
inflammatory bowel
8
ibd
5
age biologics
4
ibd management
4
goals ibd
4
management controlling
4
complications morbidity
4
clinical symptoms
4
symptoms preventing
4
shift goals
4
ibd age
4
controlling clinical
4
led shift
4
medications per-operative
4
ulcerative colitis
4
disease ulcerative
4
crohn's disease
4

References

(Supplied by CrossRef)

Similar Publications